Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Common Equity (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Common Equity for 12 consecutive years, with $107.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 557.91% year-over-year to $107.4 million, compared with a TTM value of $107.4 million through Sep 2025, up 557.91%, and an annual FY2024 reading of -$456000.0, up 99.04% over the prior year.
  • Common Equity was $107.4 million for Q3 2025 at CytomX Therapeutics, down from $119.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $119.9 million in Q2 2025 and bottomed at -$86.6 million in Q1 2023.
  • Average Common Equity over 5 years is -$9.8 million, with a median of -$29.7 million recorded in 2022.
  • The sharpest move saw Common Equity plummeted 18582.14% in 2022, then soared 557.91% in 2025.
  • Year by year, Common Equity stood at -$459000.0 in 2021, then tumbled by 18582.14% to -$85.8 million in 2022, then soared by 44.67% to -$47.4 million in 2023, then soared by 99.04% to -$456000.0 in 2024, then surged by 23650.22% to $107.4 million in 2025.
  • Business Quant data shows Common Equity for CTMX at $107.4 million in Q3 2025, $119.9 million in Q2 2025, and $25.0 million in Q1 2025.